Design Therapeutics, Inc.
DSGN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807120
No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.
Holders of 5% or more of DSGN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Design Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| SR One Capital Fund I Aggregator LP | 13D/A | 10.70%6.61M shares | – | Mar 11, 20261 filing | Mar 11, 2026 | SEC |
| Star Irrevocable Trust #1 dated April 22, 2019 | 13G/A | 6.90%3.83M shares | – | Feb 7, 20251 filing | Feb 7, 2025 | SEC |
| Light Irrevocable Trust #1 dated April 22, 2019 | 13G/A | 6.90%3.83M shares | – | Feb 7, 20251 filing | Feb 7, 2025 | SEC |
| Point72 Asset Management, L.P. | 13G | 5.10%3.20M shares | +0.70 ppfrom 4.40% | Aug 28, 20254 filings | Jun 9, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
9 Schedule 13D and 13G filings on Design Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 9, 20265:02 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.10%3.20M shares | +0.70 ppfrom 4.40% | Jun 8, 2026 | SEC |
| May 15, 20264:26 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 4.40%2.72M shares | −5.00 ppfrom 9.40%Below 5% | Mar 31, 2026 | SEC |
| Mar 11, 20269:28 PM ET | SR One Capital Fund I Aggregator LPand 3 others | 13D/A | 10.70%6.61M shares | – | Mar 9, 2026 | SEC |
| Feb 17, 20264:27 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 9.40%5.37M shares | +4.20 ppfrom 5.20% | Dec 31, 2025 | SEC |
| Nov 18, 20255:57 PM ET | Logos Global Management LPand 4 others | 13D/A | 4.40%2.52M shares | −1.30 ppfrom 5.70%Below 5% | Nov 14, 2025 | SEC |
| Nov 12, 20255:10 PM ET | Logos Global Management LPand 4 others | 13D/A | 5.70%3.25M shares | – | Nov 7, 2025 | SEC |
| Aug 28, 20254:05 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.20%2.94M shares | New | Aug 27, 2025 | SEC |
| Feb 7, 20254:16 PM ET | Star Irrevocable Trust #1 dated April 22, 2019and 1 other | 13G/A | 6.90%3.83M shares | – | Dec 31, 2024 | SEC |
| Feb 7, 20254:15 PM ET | Light Irrevocable Trust #1 dated April 22, 2019and 1 other | 13G/A | 6.90%3.83M shares | – | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Design Therapeutics, Inc. shares.
No Form 144 notices for Design Therapeutics, Inc. are on file.